
Mei Wei, MD, discusses the potential clinical implications of the ongoing, phase 3 CompassHER2 RD trial in HER2-positive breast cancer.

Your AI-Trained Oncology Knowledge Connection!


Mei Wei, MD, discusses the potential clinical implications of the ongoing, phase 3 CompassHER2 RD trial in HER2-positive breast cancer.

Mei Wei, MD, discusses the risk of interstitial lung disease with fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

Mei Wei, MD, discusses the benefits of subcutaneous administration of pertuzumab and trastuzumab in patients with HER2-positive early breast cancer.

Mei Wei, MD, discusses the efficacy of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer, as demonstrated in the DESTINY-Breast01 trial.